Peptide hormones remain among the hardest banned substances to detect in sports because they closely mimic the body's own molecules, but biomarker-based approaches offer a promising path forward.
Nearly undetectablePeptide hormones closely mimic the body's natural molecules, making many of them extremely difficult or impossible to reliably detect with current anti-doping assays
What the researchers found
Detecting peptide hormone doping in athletes remains one of the hardest challenges in anti-doping science. Unlike small-molecule drugs that leave clear metabolic traces, peptide hormones like growth hormone, EPO, and insulin-like growth factor are nearly identical to substances the body produces naturally. The review describes advances in mass spectrometry-based detection methods and immunological assays for WADA-prohibited peptides, while noting that many peptide hormones still can't be reliably detected.
The most promising future direction is the development of 'biomarker' approaches — instead of trying to detect the peptide itself, scientists look for downstream biological changes that betray its use. This indirect detection strategy may be the key to catching peptide doping.
Why it matters
Peptide hormones are among the most commonly abused substances in elite sport, but they're also among the hardest to detect. As new synthetic peptides (like growth hormone secretagogues and GLP-1 agonists) become widely available, anti-doping labs face an ever-expanding list of targets. This review maps the state of detection technology and identifies critical gaps that athletes could exploit.
The numbers in context
WADA Section S2 prohibited substances covered · MS-based and immunological assay methods reviewed · Biomarker-based detection approaches in development
How the study worked
This is an expert review authored by researchers affiliated with WADA-accredited anti-doping laboratories. It surveys published analytical methods for detecting prohibited peptide hormones, evaluates the performance of mass spectrometry and immunoassay approaches, and discusses emerging biomarker-based detection strategies under development.
Who was studied
Review covering analytical methods used in WADA-accredited anti-doping laboratories
What this study cannot tell us
As a 2012 review, the specific analytical methods described have evolved, though the fundamental challenges of peptide hormone detection remain relevant. The review focuses on detection capability rather than real-world prevalence of peptide doping, so the actual scale of the problem isn't quantified. Some newer peptides now used in sports weren't covered.
How to read the evidence
This is an expert review from researchers working within the WADA anti-doping framework. It provides authoritative coverage of analytical methods but doesn't present new experimental data. The evidence describes technological capabilities rather than clinical outcomes.
When this study was published
Published in 2012, this review captures an earlier snapshot of anti-doping analytics. While specific assay technologies have advanced significantly, the core challenge of detecting endogenous-mimicking peptides remains fundamentally unchanged. Newer peptides like GLP-1 agonists and growth hormone secretagogues weren't covered.
The bigger picture
The explosion of synthetic peptides available through research chemical suppliers and online vendors has created a new frontier for anti-doping enforcement. Growth hormone secretagogues, selective androgen modulators, and other peptides are increasingly accessible to athletes at all levels. This review highlights a fundamental tension in peptide sports regulation: detection technology consistently lags behind the availability of new performance-enhancing peptides.
Questions still open
- Have biomarker-based detection methods matured enough since 2012 to reliably catch peptide hormone doping in routine testing?
- How do anti-doping labs keep pace with the rapid proliferation of new synthetic peptides sold as research chemicals?
- Should anti-doping policy shift from trying to detect specific peptides to monitoring biological passports for suspicious changes?
Common questions
Why can't drug tests easily detect peptide hormone doping?
What are biomarkers of doping and how do they help?
Read the original research
Analytical challenges in the detection of peptide hormones for anti-doping purposes.
Bioanalysis, 4(13), 1577-90
Citation
Barroso, Osquel; Handelsman, David J; Strasburger, Christian; Thevis, Mario. (2012). Analytical challenges in the detection of peptide hormones for anti-doping purposes.. Bioanalysis, 4(13), 1577-90. https://doi.org/10.4155/bio.12.128